Givaudan stock: Barclays keeps CHF 3,950 target for Givaudan stock

Published on 10/23/2026 at 15:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Givaudan reported CHF 7,472 million in fiscal year 2025. Givaudan stock costs EUR 4,351.00 on October 23, 2026 at Lang & Schwarz in trading.

Analyst target and reporting date

Barclays maintained a CHF 3,950.00 target and Buy rating on October 14, 2026.
Givaudan reported CHF 7,472 million in fiscal year 2025 sales.
Givaudan stock costs EUR 4,351.00 at Lang & Schwarz on October 23, 2026 at 3:37 p.m. CEST.
Givaudan scheduled a Zurich investor presentation for October 29, 2026.

Givaudan CH0010645932 fotorealistisches Parfumeur-Atelier mit Reagenzgläsern, getrockneten Blüten und warmem goldenem Nachmittagslicht, Illustration mit AI erstellt.

Barclays maintained its Buy rating on Givaudan and set a CHF 3,950.00 price target on October 14, 2026, according to Markets Insider. The target is 1.40 percent below the SIX quote of CHF 4,006.00 on October 23, 2026 at 3:34 p.m. CEST. At Lang & Schwarz, Givaudan stock was trading at EUR 4,351.00 on October 23, 2026 at 3:37 p.m. CEST.

Sales provide the operating backdrop

Givaudan's most recent full-year figures show CHF 7,472 million in sales for fiscal year 2025, up 5.1 percent on a like-for-like basis from 2024. The company reported CHF 1,751 million of EBITDA and a 23.4 percent EBITDA margin for the same period, according to its investor information.

Net income reached CHF 1,071 million in fiscal year 2025, while the dividend was CHF 72.00 per share. These figures place the analyst debate against a business that expanded sales and preserved a margin above 20 percent. The reported figures come from Givaudan.

How far is the Swiss quote from its high?

The SIX quote of CHF 4,006.00 stood CHF 1.00 below the 52-week high of CHF 4,007.00 on October 23, 2026, a gap of 0.02 percent. Givaudan's market capitalization was CHF 36.98 billion, and its price-to-earnings ratio was 29.74 on the same date. Trading volume reached 7,395 shares.

Valuation and upcoming date

Barclays cited stronger growth prospects for Taste and Wellbeing when it raised its target to CHF 3,850.00 on October 5, 2026, before the later CHF 3,950.00 target cited by Markets Insider. Its earlier report also lifted the 2027 organic growth forecast to 5.8 percent from 5.0 percent and projected adjusted EBITDA of CHF 2.02 billion for 2027.

Givaudan scheduled a presentation in Zurich for October 29, 2026. The company lists the event in its investor calendar, where the presentation is set for 3:00 p.m. CET. The date is published on Givaudan's investor page.

Comparison with peers

Givaudan: 0.78 percent higher on the day, P/E 29.74, market capitalization CHF 36.98 billion.

International Flavors & Fragrances: down 0.75 percent, P/E 86.23, market capitalization USD 23.8 billion.

Sensient Technologies: down 0.28 percent, P/E 35.00, market capitalization USD 5.6 billion.

The market view stays divided

Barclays supports a CHF 3,950.00 valuation while Givaudan's reported 2025 results provide the operating reference. The narrow 0.02 percent gap to the Swiss 52-week high leaves the analyst target as the clearest valuation counterpoint.

The further course of trading is shown by the continuously updated real-time quote of Givaudan stock.